RxDoctor Payments Data

Jan Kulhanek, MD

Interventional Cardiology · Encinitas, CANPI 1316908775

Payments from drug & device makers

$15,910in general payments, 2019–2025

Across 615 payments — averaging $25.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$1K
  • Amgen$1K
  • AOP Health US, LLC$948
  • AstraZeneca$904
  • Merck$749
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$15,892100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis52$1,152
Pfizer75$1,127
Amgen43$1,022
AOP Health US, LLC2$948
AstraZeneca35$904
Merck28$749
Sanofi-aventis U.S. LLC25$717
E.r. Squibb & Sons, L.L.C.29$703
Abiomed13$622
Medtronic(2 entities)10$571
Regeneron Healthcare Solutions, Inc.22$533
Esperion Therapeutics, Inc.23$520
Cvrx, Inc.27$488
Johnson & Johnson28$482
Kestra Medical Technology Services, Inc.9$475
Abbott14$468
Boehringer Ingelheim16$426
Boston Scientific14$364
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)16$343
Actelion Pharmaceuticals US, Inc.13$337
Kiniksa Pharmaceuticals, Ltd.13$248
Irhythm Technologies, Inc.5$243
Kowa Pharmaceuticals America, Inc.20$204
Amarin Pharma, Inc.8$184
Novo Nordisk4$183
Otsuka America Pharmaceutical, Inc.8$182
Stryker1$148
Heartflow, Inc.4$144
Bardy Diagnostics, Inc.2$137
Biosense Webster, Inc.1$135
Kiniksa Pharmaceuticals International, PLC5$123
Impulse Dynamics (USA) Inc.4$118
Alnylam Pharmaceuticals Inc.4$92
Chiesi USA, Inc.5$89
Gilead4$79
Lundbeck LLC4$72
Lexicon Pharmaceuticals, Inc.3$72
Baxter Healthcare2$45
Daiichi Sankyo Inc.2$39
Lilly USA, LLC2$39
Cleerly, Inc.1$27
Convatec Inc.1$26
Biotronik Inc.1$24
Braemar Manufacturing, LLC1$24
Philips North America LLC1$24
Edwards Lifesciences1$21
Atricure, Inc.1$21
Microtransponder, Inc.1$21
Bayer1$21
Inspire Medical Systems, Inc.1$18
Bristol Myers Squibb1$18
GSK1$18
W. L. Gore & Associates, Inc.1$18
Angiodynamics, Inc.1$18
Trevena, Inc.1$16
Amryt Pharma Holdings Ltd1$15
Lantheus Medical Imaging, Inc.1$14
Itamar Medical Inc1$14
Tactile Systems Technology Inc1$13
AbbVie1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,910 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$991,610
Medicare patients
1,730
Services billed
10,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$440,464
XareltoRivaroxaban56$83,652
EntrestoSacubitril/Valsartan46$50,151
Repatha SureclickEvolocumab28$29,381
MultaqDronedarone Hcl14$26,184
FarxigaDapagliflozin Propanediol17$18,416
Valsartan313$10,443
BrilintaTicagrelor16$9,968
Metoprolol Succinate378$6,313
Nebivolol Hcl39$4,564
Ezetimibe211$4,388
Atorvastatin Calcium460$4,353
Diltiazem 24hr Er (Cd)Diltiazem Hcl116$3,976
Rosuvastatin Calcium212$3,740
Dabigatran EtexilateDabigatran Etexilate Mesylate12$3,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,127$440,464346 claims
Johnson & JohnsonXarelto$482$83,65256 claims
NovartisEntresto$1,152$50,15146 claims
AstraZenecaFarxiga, Brilinta$904$28,38533 claims
Sanofi-aventis U.S. LLCMultaq$717$26,18414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →